MA46698A - Composés de 4,4 a, 5,7-têtrahydro -3 h-furo [3,4-b]pyridinyl - Google Patents

Composés de 4,4 a, 5,7-têtrahydro -3 h-furo [3,4-b]pyridinyl

Info

Publication number
MA46698A
MA46698A MA046698A MA46698A MA46698A MA 46698 A MA46698 A MA 46698A MA 046698 A MA046698 A MA 046698A MA 46698 A MA46698 A MA 46698A MA 46698 A MA46698 A MA 46698A
Authority
MA
Morocco
Prior art keywords
têtrahydro
furo
pyridinyl
compounds
Prior art date
Application number
MA046698A
Other languages
English (en)
Inventor
Henricus Jacobus Maria Gijsen
Frederik Jan Rita Rombouts
Brandt Sven Franciscus Anna Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA46698A publication Critical patent/MA46698A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA046698A 2016-11-04 2017-11-03 Composés de 4,4 a, 5,7-têtrahydro -3 h-furo [3,4-b]pyridinyl MA46698A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16197351 2016-11-04
EP17162307 2017-03-22

Publications (1)

Publication Number Publication Date
MA46698A true MA46698A (fr) 2021-04-07

Family

ID=60413151

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046698A MA46698A (fr) 2016-11-04 2017-11-03 Composés de 4,4 a, 5,7-têtrahydro -3 h-furo [3,4-b]pyridinyl

Country Status (10)

Country Link
US (1) US20200062773A1 (fr)
EP (1) EP3535271A1 (fr)
JP (1) JP2019532992A (fr)
KR (1) KR20190075072A (fr)
CN (1) CN109890828A (fr)
AU (1) AU2017353510A1 (fr)
CA (1) CA3039586A1 (fr)
MA (1) MA46698A (fr)
MX (1) MX2019005247A (fr)
WO (1) WO2018083247A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
CN104870000A (zh) * 2012-12-20 2015-08-26 默沙东公司 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途
JP2017538753A (ja) 2014-12-18 2017-12-28 ヤンセン ファーマシューティカ エヌ．ベー． ２，３，４，５−テトラヒドロピリジン−６−アミンおよび３，４−ジヒドロ−２Ｈ−ピロール−５−アミンの化合物のβセクレターゼ阻害剤
JP2018527338A (ja) * 2015-08-12 2018-09-20 ハー・ルンドベック・アクチエゼルスカベット ＢＡＣＥ１阻害剤としての２−アミノ−７ａ−フェニル−３，４，４ａ，５，７，７ａ−ヘキサヒドロフロ［３，４−ｂ］ピリジン

Also Published As

Publication number Publication date
EP3535271A1 (fr) 2019-09-11
MX2019005247A (es) 2019-06-24
AU2017353510A1 (en) 2019-05-02
CN109890828A (zh) 2019-06-14
US20200062773A1 (en) 2020-02-27
JP2019532992A (ja) 2019-11-14
WO2018083247A1 (fr) 2018-05-11
CA3039586A1 (fr) 2018-05-11
KR20190075072A (ko) 2019-06-28

Similar Documents

Publication Publication Date Title
EP3802467A4 (fr) Composés spirocycliques
EP3781156A4 (fr) Composés spirocycliques
EP3523306A4 (fr) Composés spirocycliques
EP3558322A4 (fr) Composés benzyl-amide phosphodiamide antiviraux
EP3720430A4 (fr) Composés benzocarbonyle
EP3532069A4 (fr) Composés aryl-amide phosphodiamide antiviraux
ZA201903708B (en) New anthelmintic quinoline-3-carboxamide derivatives
EP3691623A4 (fr) Composés de benzosulfonyle
EP3474845A4 (fr) Composés immunomodulateurs
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
DK3355884T3 (da) Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
EP3445750A4 (fr) Composés thérapeutiques
EP3452481A4 (fr) Imidazo[1,2-b]pyridazines substituées, imidazo[1,5-b]pyridazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux
LT3180314T (lt) Sintetinių tarpinių junginių, skirtų tetrahidrochinolino darinių gamybai, gavimo būdas
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
ME03419B (fr) Composés dihydroisoquinolinone substitués
EP3551176A4 (fr) Composés hétérocycliques antidiabétiques
EP3436003A4 (fr) Composés bicycliques antidiabétiques
EP3386952A4 (fr) Composés de benzimidazolium, pyrido-imidazolium ou pyrazino-imidazolium substitués utilisés comme agents chimiothérapeutiques
EP3464336A4 (fr) Composés
EP3709995A4 (fr) Composés bicycliques antidiabétiques
EP3405455A4 (fr) Composés de 2-oxindole
HUE054815T2 (hu) 3,5-Difenil-diazol vegyületek vízoldható származékai
MA51221A (fr) Composés de pyrazolopyridinone